Drozitumab

Drozitumab ^?
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	DR5
Clinical data
Pregnancy cat.	?
Legal status	?
Identifiers
CAS number	912628-39-8^N
ATC code	None
UNII	SQ67484MA7^Y
Chemical data
Formula	C₆₃₃₄H₉₇₉₂N₁₇₀₀O₂₀₀₀S₄₂
Mol. mass	143.1 kDa
N(what is this?) (verify)

Drozitumab is a human monoclonal antibody designed for the treatment of cancers.^[1]

Drozitumab was developed by Genentech.

References

^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Drozitumab". American Medical Association. http://www.ama-assn.org/resources/doc/usan/drozitumab.pdf.

Monoclonal antibodies for tumors

Tumor ("-t(u[m])-")

Human ("-tumu-")	Adecatumumab • Belimumab • Cixutumumab • Conatumumab • Daratumumab • Drozitumab • Figitumumab • Ganitumab • Glembatumumab vedotin • Intetumumab • Iratumumab • Lexatumumab • Lucatumumab • Mapatumumab • Narnatumab • Necitumumab • Ofatumumab • Olaratumab • Panitumumab • Pritumumab • Radretumab • Rilotumumab • Robatumumab • Teprotumumab • Votumumab • Zalutumumab "-melu-" (melanoma): Flanvotumab

Mouse ("-tumo-")	Altumomab pentetate • Anatumomab mafenatox • Arcitumomab • Bectumomab • Blinatumomab • CC49 • Detumomab • Ibritumomab tiuxetan • Minretumomab • Mitumomab • Moxetumomab pasudotox • Naptumomab estafenatox • Nofetumomab merpentan • Pemtumomab^† • Pintumomab • Racotumomab • Satumomab pendetide • Taplitumomab paptox • Tenatumomab • Tositumomab • 3F8 "-govo-" (ovarian tumor): Abagovomab • Igovomab • Oregovomab "-pro-" (prostate tumor): Capromab pendetide "-colo-" (colonic tumor): Edrecolomab • Nacolomab tafenatox

Chimeric ("-tuxi-")	Amatuximab • Bavituximab • Brentuximab vedotin • Cetuximab • Ensituximab • Girentuximab • Indatuximab ravtansine • Rituximab • Siltuximab • Ublituximab "-mexi-" (melanoma): Ecromeximab

Humanized ("-tuzu-")	Afutuzumab • Alemtuzumab • Bevacizumab • Bivatuzumab mertansine • Cantuzumab mertansine • Cantuzumab ravtansine • Citatuzumab bogatox • Clivatuzumab tetraxetan • Dacetuzumab • Dalotuzumab • Elotuzumab^† • Etaracizumab • Farletuzumab • Ficlatuzumab • Gemtuzumab ozogamicin • Inotuzumab ozogamicin • Labetuzumab • Lintuzumab • Lorvotuzumab mertansine • Matuzumab^§ • Milatuzumab • Nimotuzumab • Onartuzumab • Oportuzumab monatox • Pertuzumab • Sibrotuzumab • Tacatuzumab tetraxetan • Tigatuzumab • Trastuzumab • Tucotuzumab celmoleukin • Veltuzumab

Rat/mouse hybrid ("-tumaxo-")	Catumaxomab • Ertumaxomab

^#WHO-EM. ^‡Withdrawn from market. Clinical trials: ^†Phase III. ^§Never to phase III